Gemcitabine in non-small cell lung cancer (NSCL)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023841%3A_____%2F00%3A00005632" target="_blank" >RIV/00023841:_____/00:00005632 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Gemcitabine in non-small cell lung cancer (NSCL)

Original language description

The role of chemotherapy in the treatment of non-small cell lung cancer (NSCLC) has increased greatly in the past few years. While cytotoxic drugs are currently used both as single agents and combination for palliation in locally advenced and metastaticdisease, they have also been incorporated into multi-modality treatment strategies of Stage I to Stage III. NSCLC. One of the mains reason for the increased acceptance of chemotherapy is the devolepment of new substances.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NC6070" target="_blank" >NC6070: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in non-small cell lung cancer stage IIIB and IV. A randomized study.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2000

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Investigational New Drugs

ISSN

—

e-ISSN

—

Volume of the periodical

18

Issue of the periodical within the volume

1

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

3

Pages from-to

29-42

UT code for WoS article

—

EID of the result in the Scopus database

—